Related references
Note: Only part of the references are listed.Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10002
David A. Rizzieri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
Luciano J. Costa et al.
BLOOD (2013)
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
Shimin Hu et al.
BLOOD (2013)
Population-Based Prognostic Factors for Survival in Patients With Burkitt Lymphoma
Jorge J. Castillo et al.
CANCER (2013)
Dose-Intensive Chemotherapy Including Rituximab in Burkitt's Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status Final Results of a Phase 2 Study (Burkimab)
Josep-Maria Ribera et al.
CANCER (2013)
Low-Intensity Therapy in Adults with Burkitt's Lymphoma
Kieron Dunleavy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas
Gabriel D. Victora et al.
BLOOD (2012)
Epidemiology: clues to the pathogenesis of Burkitt lymphoma
Ian Magrath
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
The genetic landscape of mutations in Burkitt lymphoma
Cassandra Love et al.
NATURE GENETICS (2012)
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing
Julia Richter et al.
NATURE GENETICS (2012)
The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry
David Dominguez-Sola et al.
NATURE IMMUNOLOGY (2012)
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers
Dinis Pedro Calado et al.
NATURE IMMUNOLOGY (2012)
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
J. A. Barnes et al.
ANNALS OF ONCOLOGY (2011)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma
D. Lenze et al.
LEUKEMIA (2011)
AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?
Mercy Guech-Ongey et al.
BLOOD (2010)
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
Milena Sant et al.
BLOOD (2010)
Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology
Martin Rowe et al.
SEMINARS IN CANCER BIOLOGY (2009)
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Graham M. Mead et al.
BLOOD (2008)
Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL/6J mice
Myung-Soo Kang et al.
JOURNAL OF VIROLOGY (2008)
Molecular diagnosis of Burkitt's lymphoma
Sandeep S. Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
Michael Hummel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma
KW Song et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
DA Thomas et al.
CANCER (2006)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
Burkitt lymphoma in adults:: a prospective study of 72 patients treated with an adapted pediatric LMB protocol
M Diviné et al.
ANNALS OF ONCOLOGY (2005)
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
MT Hemann et al.
NATURE (2005)
Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas
C Bellan et al.
BLOOD (2005)
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma
GW van Imhoff et al.
LEUKEMIA (2005)
Endemic Burkitt's lymphoma: a polymicrobial disease?
R Rochford et al.
NATURE REVIEWS MICROBIOLOGY (2005)
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma - Final results of cancer and leukemia group B study 9251
DA Rizzieri et al.
CANCER (2004)
Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity
A Lacasce et al.
LEUKEMIA & LYMPHOMA (2004)
Gender and age-related differences in Burkitt lymphoma - epidemiological and clinical data from The Netherlands
EG Boerma et al.
EUROPEAN JOURNAL OF CANCER (2004)
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
S Smeland et al.
ANNALS OF ONCOLOGY (2004)
Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples
E Haralambieva et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study
GM Mead et al.
ANNALS OF ONCOLOGY (2002)
De novo CD5+ diffuse large B-cell lymphoma:: a clinicopathologic study of 109 patients
M Yamaguchi et al.
BLOOD (2002)
Share Paper
